Corecam Pte. Ltd. increased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 9.0% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 322,630 shares of the biopharmaceutical company’s stock after purchasing an additional 26,700 shares during the period. Pfizer accounts for about 2.9% of Corecam Pte. Ltd.’s investment portfolio, making the stock its 14th biggest holding. Corecam Pte. Ltd.’s holdings in Pfizer were worth $7,769,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Vanguard Group Inc. grew its position in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after acquiring an additional 7,031,162 shares in the last quarter. State Street Corp raised its position in shares of Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after acquiring an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Pfizer by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after acquiring an additional 1,184,728 shares in the last quarter. Morgan Stanley lifted its stake in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the last quarter. Finally, Norges Bank acquired a new position in Pfizer in the fourth quarter worth $1,830,986,000. Institutional investors and hedge funds own 68.36% of the company’s stock.
Key Pfizer News
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer CEO Albert Bourla purchased approximately $1 million of company stock, adding 38,000 shares. The insider purchase may signal management’s confidence that the shares are undervalued. Pfizer CEO Buys $1 Million of Stock
- Positive Sentiment: Pfizer’s second-quarter results exceeded expectations, and management modestly raised 2026 revenue guidance to $60.5 billion-$62.5 billion. Analysts also highlighted stable core operations, strength from acquired brands and recent launches, and momentum in the non-COVID business. 5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
- Positive Sentiment: Positive Phase 3 results for LITFULO in nonsegmental vitiligo strengthen Pfizer’s immunology pipeline and support the company’s effort to replace declining COVID-related revenue with newer products. Pfizer’s Higher 2026 Guidance and LITFULO Trial Results
- Positive Sentiment: Recent coverage points to growing investor interest in Pfizer’s launches, acquisitions and pipeline as potential drivers of longer-term growth, particularly from 2029 onward. Will Pfizer’s Non-COVID Portfolio Drive Its Next Phase of Growth?
- Neutral Sentiment: Analysts remain broadly focused on Pfizer’s valuation and earnings outlook; Erste Group raised its 2026 EPS estimate to $2.95 from $2.92, close to the approximately $2.98 consensus. Analysts Offer Insights on Healthcare Companies
- Negative Sentiment: Pfizer discontinued hemophilia gene therapy BEQVEZ as the commercial market contracts and physicians demand longer-term efficacy data, removing a potential growth contributor. Gene Therapy Remains Top-of-Mind in Hemophilia
- Negative Sentiment: Pfizer agreed to a $44 million class-action settlement related to Chantix safety-disclosure claims. The financial charge is manageable relative to Pfizer’s size but highlights continuing litigation exposure. Pfizer Agreed to a $44 Million Chantix Settlement
- Negative Sentiment: Arbutus filed additional patent-enforcement lawsuits against Pfizer and BioNTech concerning lipid nanoparticle technology, creating another potential legal overhang tied to COVID vaccine intellectual property. Arbutus Reports Second-Quarter Results
Pfizer Trading Up 1.9%
Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.
Pfizer Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.
Wall Street Analyst Weigh In
Several analysts have weighed in on PFE shares. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $28.00 in a research note on Monday, July 6th. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. Citigroup lifted their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Finally, CICC Research initiated coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.28.
Read Our Latest Stock Analysis on Pfizer
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
- Five stocks we like better than Pfizer
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
